Recombinant C9 antibody (C-Term)

Catalog No. ABIN8093099

The Mouse Monoclonal anti-C9 antibody is suitable to detect C9 in samples from Human. It has been validated for IHC.

Quick Overview for Recombinant C9 antibody (C-Term) (ABIN8093099)

Target: C9 (Complement Component C9 (C9))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This C9 antibody is un-conjugated

Application: Immunohistochemistry (IHC)

Grade: Carrier-free

Clone: R10A6

Product Details anti-C9 Antibody

Binding Specificity: C-Term

Purpose: C9 Antibody / Complement component 9 (azide and preservative free)

Immunogen: Prokaryotic recombinant protein corresponding to a C-terminal region of the Complement component C9 molecule was used as the immunogen for the Complement C9/C9 Protein antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: 1. Optimal dilution of the Complement C9/C9 Protein antibody should be determined by the researcher.

2. This Complement C9/C9 Protein antibody is recombinantly produced by expression in CHO cells.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C,-80 °C

Storage Comment: Complement C9/C9 Protein antibody with sodium azide - store at 2 to 8oC, antibody without sodium azide - store at -20 to -80oC.

Target Details for C9

Target: C9 (Complement Component C9 (C9))

Alternative Name: C9

Background: Complement C9 antibody recognizes Complement component 9, also referred to as C9 protein, a terminal component of the complement cascade encoded by the C9 gene. Complement C9 is a secreted glycoprotein that plays a critical role in innate immunity through its participation in formation of the membrane attack complex. This complex is responsible for creating transmembrane pores in target cell membranes, leading to osmotic lysis of bacteria and other susceptible cells. Complement C9 antibody supports investigation of terminal complement pathway activation and immune mediated tissue injury.

Complement component 9 belongs to the membrane attack complex perforin family of pore forming proteins. Activation of the classical, lectin, or alternative complement pathways results in cleavage of C5 and assembly of the C5b-6-7-8 complex on target membranes. Multiple C9 Molecules then bind and polymerize, forming a circular pore structure that inserts into the lipid bilayer. This polymerization step is essential for full lytic activity. Detection of C9 protein therefore provides evidence of membrane attack complex formation and complement mediated cytotoxicity.

C9 protein is synthesized predominantly by hepatocytes and secreted into the circulation as a soluble monomer. Under physiologic conditions, it is found in plasma and serum. Tissue deposition of Complement C9 is typically observed along cell membranes in settings of complement activation, including autoimmune disease, transplant rejection, and certain infectious processes. Increased C9 deposition has been documented in renal pathologies, systemic inflammatory conditions, and antibody mediated injury.

The C9 gene is located on chromosome 5p13.1 and encodes a protein containing the membrane attack complex perforin domain responsible for pore formation. Structural rearrangements allow C9 to transition from a soluble monomer to a membrane inserted polymer during complement activation. Complement C9 antibody clone r10A6 is a recombinant mouse monoclonal antibody designed to detect C9 protein in research applications, supporting studies of complement activation, immune pathology, and inflammatory microenvironments.

UniProt: P02748

Pathways: Complement System